Ozempic and Gastroparesis: What the Warning Means for Your Health

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health to Specific Exposure Concerns

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering whether the medication could be linked to gastroparesis—a condition where the stomach empties too slowly. For decades, medical research has recognized that certain drugs can affect gastrointestinal motility, and recent pharmacovigilance data has prompted regulatory scrutiny of GLP-1 receptor agonists. This page explains the FDA warning, what the science says, and what you should watch for.

Bridging to Ozempic and Gastroparesis

Building on the need to adapt health frameworks, we now turn to a specific concern: the potential link between Ozempic (semaglutide) and gastroparesis. Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in those with established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Its mechanism involves slowing gastric emptying, which contributes to glycemic control but also raises concerns about gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical presentation of gastroparesis overlaps with common gastrointestinal adverse effects reported in Ozempic trials. In placebo-controlled studies, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In trials with 1 mg and 2 mg doses, gastrointestinal adverse reactions occurred more frequently with 2 mg (34.0%) versus 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal reactions reported at frequencies below 5% include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Mechanistic Evidence and Clinical Presentation

Mechanistically, GLP-1 receptor agonists like Ozempic delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can mimic or exacerbate gastroparesis. While transient slowing is intended for glycemic control, persistent or severe delay may lead to gastroparesis-like symptoms. The reported adverse events—nausea, vomiting, dyspepsia, and gastroesophageal reflux—are consistent with gastroparesis presentation. However, the label does not explicitly list gastroparesis as a distinct adverse reaction, instead grouping these under gastrointestinal adverse reactions. This raises questions about the adequacy of warnings regarding Ozempic and gastroparesis. The label notes that Ozempic has not been studied in patients with a history of pancreatitis and recommends considering other therapies in such patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but no similar precaution exists for gastroparesis or severe gastric emptying delay.

Causation Considerations and Risk Context

For affected patients, causation considerations involve several factors. First, the temporal relationship: gastrointestinal symptoms often emerge during dose escalation, as noted in trials (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This suggests a dose-dependent effect, with higher doses (2 mg) associated with more frequent gastrointestinal adverse reactions than lower doses (1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Second, the biological plausibility is supported by the known pharmacology of GLP-1 agonists. Third, alternative causes must be excluded, such as diabetic gastroparesis (common in type 2 diabetes), mechanical obstruction, or other medications. The label’s limitation that Ozempic has not been studied in patients with a history of pancreatitis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166) underscores the need for caution in patients with pre-existing gastrointestinal conditions. The timeline between exposure and documented harm is critical. In trials, gastrointestinal adverse reactions were most common during dose escalation, but some patients discontinued due to these reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). For patients who develop persistent symptoms after dose stabilization, a causal link may be more difficult to establish, as symptoms could reflect underlying diabetic gastroparesis. However, the higher incidence in Ozempic-treated patients versus placebo supports a drug-related effect. Risk considerations for patients include the potential for severe gastrointestinal adverse reactions leading to discontinuation. The label reports that 3.1% to 3.8% of patients discontinued due to gastrointestinal adverse reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). For those who develop gastroparesis-like symptoms, management may involve dose reduction, temporary discontinuation, or switching to an alternative therapy. The absence of explicit gastroparesis warnings may delay recognition and treatment.

Summary and Recommendations

In summary, while Ozempic’s label documents gastrointestinal adverse reactions consistent with gastroparesis, it does not specifically warn about gastroparesis as a distinct risk. The mechanistic link through delayed gastric emptying is plausible, and the temporal pattern during dose escalation supports causation in some patients. Affected individuals should discuss symptoms with their healthcare provider, particularly if symptoms persist or worsen. Further research is needed to clarify the incidence of gastroparesis specifically, as opposed to general gastrointestinal adverse reactions, in Ozempic users. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) slows gastric emptying as part of its mechanism, which can mimic or exacerbate gastroparesis—a condition of delayed gastric emptying. Clinical trials show higher rates of gastrointestinal adverse reactions like nausea and vomiting in Ozempic users compared to placebo, but the label does not explicitly list gastroparesis as a distinct risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

How common are gastrointestinal side effects with Ozempic?

In placebo-controlled studies, gastrointestinal adverse reactions occurred in 32.7% of patients on 0.5 mg and 36.4% on 1 mg Ozempic, compared to 15.3% on placebo. Discontinuation due to these reactions was 3.1% and 3.8% for the two doses, versus 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Should I stop taking Ozempic if I have gastroparesis symptoms?

If you experience persistent nausea, vomiting, or abdominal pain, consult your healthcare provider. They may recommend dose adjustment, temporary discontinuation, or switching to another therapy. Do not stop without medical advice.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.